Company Analysis Codex DNA, Inc.
1. Summary
Advantages
- Price (1.3 $) is less than fair price (8.47 $)
Disadvantages
- Dividends (0%) are below the sector average (0.5526%).
- The stock's return over the last year (-79.36%) is lower than the sector average (-48.76%).
- Current debt level 79.66% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-67.7%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Codex DNA, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 14.3% | 3.1% | 0.4% |
| 90 days | 63.9% | -35.4% | 13.7% |
| 1 year | -79.4% | -48.8% | 36.2% |
DNAY vs Sector: Codex DNA, Inc. has significantly underperformed the "Healthcare" sector by -30.6% over the past year.
DNAY vs Market: Codex DNA, Inc. has significantly underperformed the market by -115.59% over the past year.
Stable price: DNAY is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: DNAY with weekly volatility of -1.53% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (1.3 $) is lower than the fair price (8.47 $).
Price significantly below the fair price: The current price (1.3 $) is 551.5% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (48.3).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.66) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (0.66) is lower than that of the market as a whole (3.18).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.68) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (1.68) is lower than that of the market as a whole (10.18).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.24) is higher than that of the sector as a whole (-22.31).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.24) is lower than that of the market as a whole (18.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 86% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (86%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (-67.7%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-67.7%) is lower than that of the market as a whole (10.9%).
5.5. ROA
ROA vs Sector: The company's ROA (-29.63%) is lower than that of the sector as a whole (0.3359%).
ROA vs Market: The company's ROA (-29.63%) is lower than that of the market as a whole (6.48%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-109.21%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-109.21%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5526%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
